Healthcare, Pharma & Life Sciences

U.S. Senate Passes SBIR/STTR Reauthorization, Restoring Critical Funding for Medtech Startups

Image

SHERIDAN, WYOMING - April 12, 2026 - The U.S. Senate passed legislation reauthorizing the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which had lapsed on September 30, 2025, cutting off competitive grant access for early-stage medtech companies. AdvaMed, the Medtech Association, publicly supported the Senate vote and called on the House of Representatives to act swiftly on passage. The programs channel competitive grants through 11 federal agencies - including the National Institutes of Health, the National Science Foundation, and the Department of Defense - directly to small medtech businesses at the most capital-constrained stages of product development. Restoring authorization removes a period of funding uncertainty that had stalled R&D planning across hundreds of early-stage medical device companies.

SBIR and STTR Reauthorization Clears Senate, Moving Medtech Startup Funding One Step Closer to Restoration

SHERIDAN, WYOMING - April 12, 2026 - Early-stage medtech companies that lost access to federal competitive grant funding when SBIR and STTR program authorization lapsed on April 12, 2026, now face a clearer path to restored capital after both chambers of Congress advanced reauthorization legislation. The Senate passed the measure first, followed by House passage of S. 3971, the Small Business Innovation and Economic Security Act, on April 12, 2026, bringing the programs within reach of full restoration pending presidential signature.

ABK Biomedical Completes Enrollment in ROUTE90 Pivotal FDA IDE Study for Liver Cancer Treatment

Image

SHERIDAN, WYOMING - April 12, 2026 - ABK Biomedical has completed enrollment of all 120 patients in ROUTE90, its pivotal U.S. FDA Investigational Device Exemption study evaluating Eye90 microspheres® for unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The milestone positions the Halifax-based medical device company to finalize one-year patient follow-up, then submit a Premarket Approval (PMA) application to the FDA. Eye90 microspheres hold FDA Breakthrough Device Designation, signaling regulatory recognition of the device's potential to address an unmet clinical need in liver cancer care.

Septodont's Biodentine and BioRoot Flow Clinical Data Reshape Restorative and Endodontic Protocols in 2026

SHERIDAN, WYOMING - April 10, 2026 - Dental clinicians managing deep cavity restorations and endodontic retreatment decisions now have a richer evidence base to draw from, as Septodont USA's February 2026 clinical newsletter consolidates two-year trial outcomes for BioRoot® Flow and four documented case studies applying Biodentine® in the Bio-Bulk Fill technique for indirect restorations.

Biodentine Bio-Bulk Fill: four clinical cases document deep cavity restoration

Septodont's Case Studies Collection 28 presents workflows from four clinicians who used Biodentine®'s dentine-like mechanical and biological properties to restore deep cavities using the Bio-Bulk Fill technique. The cases extend the application of the material to symptomatic cracked teeth - a notoriously difficult clinical scenario where pulp status is uncertain and cavity geometry is irregular.

TÜV Association's 2026 Plant Safety Report Highlights Regulatory Pressure on Industrial Facility Operators

SHERIDAN, WYOMING - April 10, 2026 - Industrial facility operators across Germany and the broader DACH region face tightening inspection and compliance requirements in 2026, as the TÜV Association's annual Plant Safety Report (Anlagensicherheitsreport) documents the current state of accident prevention, technical inspections, and regulatory oversight for hazardous installations. The report forms a critical reference point for plant managers, insurers, and regulators assessing risk exposure across chemical, energy, and heavy manufacturing sectors.

AdvaMed Backs USMCA Renewal, Citing Supply Chain Stability and Medtech Export Leadership

SHERIDAN, WYOMING - April 09, 2026 - Medtech supply chains across North America depend on the continued operation of the United States-Mexico-Canada Agreement, and a formal renewal keeps tariff predictability intact for the more than 650 medtech and health tech companies that AdvaMed represents - the majority of them small businesses.

Why USMCA matters to the medtech sector

The U.S. medtech industry spans manufacturing, research and development, and global healthcare delivery. Cross-border supply chains between the United States, Mexico, and Canada underpin both domestic production and the export leadership that U.S. medtech companies hold internationally. Without a stable trilateral trade framework, manufacturers face uncertainty in sourcing components, managing regulatory timelines, and forecasting capital investments.

ETSI Issues Statement on European Standardisation and the Forthcoming European Product Act

SHERIDAN, WYOMING - April 09, 2026 - Product manufacturers and technology vendors selling into the European Union face a shifting compliance landscape as the European Commission advances its forthcoming European Product Act, prompting ETSI - the European Telecommunications Standards Institute - to publish a formal statement on the role of European standardisation in shaping that legislation.

What the European Product Act means for standards

The European Product Act is expected to consolidate and modernise the EU's product legislation framework, placing harmonised standards at the centre of conformity assessment. ETSI's statement positions European standardisation bodies as essential partners in the regulatory process, arguing that technically rigorous, consensus-based standards are the most reliable mechanism for translating legislative requirements into actionable product specifications.

AdvaMed urges House action after Senate approves SBIR and STTR reauthorization

WASHINGTON, 4 March 2026: AdvaMed said the U.S. Senate has approved legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, and the association called on the House of Representatives to move quickly on passage. The medtech trade group said the vote matters because authorization for the two programs lapsed on 30 September 2025, leaving early-stage medical technology companies without the certainty they need as they pursue product research and development.

FDA-Cleared Dental-Dedicated MRI from Dentsply Sirona and Siemens Healthineers Opens Radiation-Free Soft Tissue Diagnostics for Dental Clinics

Image

SHERIDAN, WYOMING - April 04, 2026 - Radiation-free soft tissue imaging is now clinically validated and FDA-cleared for in-clinic dental diagnostics, shifting the diagnostic standard beyond cone-beam CT and X-ray for periodontitis, TMJ disorders, endodontics, and orthodontics assessment. The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona in partnership with Siemens Healthineers, is the world's first dental-dedicated MRI (ddMRI) system, and its clearance marks a structural change in what diagnostic workflows dental practices can deploy independently - without referral to external radiology centers.

Dentsply Sirona and Siemens Healthineers Achieve FDA Clearance for MAGNETOM Free.Max Dental Edition, the First Dental-Dedicated MRI

Image

SHERIDAN, WYOMING - April 04, 2026 - Dental diagnostic practice faces a structural shift as the first commercially positioned dental-dedicated MRI (ddMRI) clears FDA review, enabling clinicians to visualize soft tissue, nerves, cartilage, and active inflammation without ionizing radiation - capabilities no CBCT or conventional X-ray system can match. The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona in collaboration with Siemens Healthineers, now holds FDA clearance following validation in a clinical trial, placing radiation-free soft tissue diagnostics within reach of in-clinic dental settings for the first time.